BioCentury
ARTICLE | Clinical News

Replidyne stops faropenem Phase III

April 24, 2008 1:10 AM UTC

Replidyne (NASDAQ:RDYN) discontinued enrollment in a placebo-controlled Phase III trial of faropenem medoxomil to treat acute exacerbations of chronic bronchitis (AECB). The company said it took the action to conserve cash. The AECB trial was one of four trials, including two in acute bacterial sinusitis (ABS) and one in community-acquired pneumonia (CAP), recommended by FDA in a not approvable letter in October 2006. Replidyne has not started the other three trials, and further development of faropenem will depend on securing a partner for the oral penem antibiotic.

At March 31, Replidyne had $78 million in cash. The company, which restructured last December, had a 2007 operating profit of $2.2 million (See BioCentury Extra, Monday, Dec. 10, 2007). ...